News

MONALEESA-2 is a pivotal Phase III trial of LEE011 (ribociclib), a cyclin dependent kinase inhibitor (CDK4/6), in combination with letrozole, compared to letrozole alone in postmenopausal women who

Noyada is an oral liquid version of captopril used in the treatment of paediatric chronic heart failure. Cevidra Laboratories, a French-based pharmaceutical company which specialises in ATU programmes

The second part will see 48 additional heavily pre-treated patients with HER2-positive breast cancer enrolled into the SYD985.001 trial. This marks an important next step in the development

"Dosing the first patient in our Phase 3 program is an important milestone for RDD Pharma in the development of our lead product candidate," said Jason Laufer, CEO

The announcement is part of a 2016 multimillion-dollar capital investment in instrumentation, which comes in the wake of ABC’s acquisition by California-based EAG in July of last year.

The approval pertains to patients who have locally advanced or metastatic urothelial carcinoma that progressed during or after platinum-based chemotherapy, or within 12 months of receiving either neoadjuvant

The variant, a twelve-letter deletion in the ASGR1 gene on chromosome 17, was discovered by analyzing the entire genome and clinical information from across the population of Iceland.

The proceeds from the financing will be used to advance Mitochon’s lead compound MP101, a first in class mitochondrial targeted neuro-protective agent, into human studies, as well as,

The application was submitted to the FDA by Novartis in March 2016 under the ofatumumab collaboration between Novartis and Genmab. Priority Review is an FDA designation for drugs